Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||ADXS-503 + Pembrolizumab|
ADXS-503 is an attenuated Listeria monocytogenes expressing tumor specific hotspot antigens, including KRAS G12D, which may induce cytotoxic immune response against tumor cells (Cancer Res 2018; 78 (13 Suppl):Abstract nr LB-149).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ADXS-503||ADXS-HOT|ADXS503|ADXS 503||ADXS-503 is an immunotherapy based on a Listeria monocytogenes strain expressing tumor-specific hotspot antigens, including KRAS G12D, which may result in increased anti-tumor immune response and decreased tumor growth (Cancer Res 2018; 78 (13 Suppl):Abstract nr LB-149).|
|Pembrolizumab||Keytruda||MK-3475||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 66||Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous squamous cell carcinoma, MSI-H or dMMR or TMB high advanced solid tumors, PD-L1 expressing NSCLC, gastric and GEJ adenocarcinoma, squamous esophageal carcinoma, and cervical cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, with axitinib in RCC, and with Lenvatinib in endometrial carcinoma that is not MSI-H or dMMR (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||ADXS-503 + Pembrolizumab||Phase I||Actionable||In a Phase I trial, ADXS-503 and Keytruda (pembrolizumab) combination therapy demonstrated manageable toxicity, resulted in stable disease as best response in 1 of 2 patients with metastatic non-small cell lung cancer (J Clin Oncol 38: 2020 (suppl; abstr e21682); NCT03847519).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03847519||Phase Ib/II||ADXS-503 + Pembrolizumab ADXS-503||Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer||Recruiting|